Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 11, 2014, Pages 1887-1893.e3

  Osterman, Mark T ^a   Aberra, Faten N ^a   Cross, Raymond ^c,i   Liakos, Steven ^d   McCabe, Robert ^e   Shafran, Ira ^f   Wolf, Douglas ^g,k   Hardi, Robert ^h   Nessel, Lisa ^b   Brensinger, Colleen ^b   Gilroy, Erin ^b   Lewis, James D ^a,b   Shah, Samir ^j   Chasen, Richard ^l   Persky, Seth ^m   Katz, Seymour ⁿ   Phillips, Raymond ^o   Geenan, Daniel ^p   Sherman, Alex ^q  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d South Jersey Gastroenterology   (United States)

^e Minnesota Gastroenterology   (United States)

^f Shafran Gastroenterology Center   (United States)

^g Atlanta Gastroenterology Associates   (United States)

^h GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Gastroenterology Associates   (United States)

^k Atlanta Gastroenterology Associates   (United States)

^l Maryland Digestive Disease Center   (United States)

^m Gastrointestinal Research Assoc LLC   (United States)

ⁿ Long Island Clinical Research Associates   (United States)

^o Naples Heart Group   (United States)

^p Wisconsin Center for Advanced Research   (United States)

^q The Concord Medical Group   (United States)

more..

Author keywords

5 Aminosalicylate; 5 ASA; Biomarker; MMX; Natural History

Indexed keywords

CALGRANULIN; FECAL CALPROTECTIN; MESALAZINE; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ACNE; ADULT; BLEEDING; BLOATING; COLITIS; CONSTIPATION; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRY EYE; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HEART PALPITATION; HUMAN; HUMAN CELL; IRON DEFICIENCY; LOW BACK PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NOTE; OCULAR PRURITUS; OPEN STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; QUIESCENT ULCERATIVE COLITIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SCORING SYSTEM; SIMPLE CLINICAL COLITIS ACTIVITY INDEX SCORE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CHEMISTRY; CLINICAL TRIAL; COLITIS, ULCERATIVE; FECES; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MESALAMINE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 84908246338     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.03.035     Document Type: Article

References (16)

1. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
2. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 140:1817-1826. e2.
3. Mao R., Xiao Y.L., Gao X., et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012, 18:1894-1899.
4. Walmsley R.S., Ayres R.C., Pounder R.E., et al. Asimple clinical colitis activity index. Gut 1998, 43:29-32.
5. Su C., Lewis J.D., Goldberg B., et al. Ameta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007, 132:516-526.
6. Molander P., af Bjorkesten C.G., Mustonen H., et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis 2012, 18:2011-2017.
7. De Vos M., Dewit O., D'Haens G., et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. JCrohns Colitis 2012, 6:557-562.
8. Vos M.D., Louis E.J., Jahnsen J., et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013, 19:2111-2117.
9. Hanauer S.B., Sandborn W.J., Dallaire C., et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007, 21:827-834.
10. Hanauer S.B., Sandborn W.J., Kornbluth A., et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005, 100:2478-2485.
11. Sandborn W.J., Regula J., Feagan B.G., et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009, 137:1934-1943. e1-3.
12. Lichtenstein G.R., Ramsey D., Rubin D.T. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011, 33:672-678.
13. Lichtenstein G.R., Kamm M.A., Sandborn W.J., et al. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 2008, 27:1094-1102.
14. Kamm M.A., Lichtenstein G.R., Sandborn W.J., et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009, 15:1-8.
15. Feagan B.G., Sandborn W.J., D'Haens G., et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013, 145:149-157. e2.
16. Feagan B.G., Chande N., Macdonald J.K. Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane Reviews. Inflamm Bowel Dis 2013, 19:2031-2040.